{"id":"W4246625087","doi":"10.1200/jco.2016.34.15_suppl.lba4500","title":"Atezolizumab (atezo) as first-line (1L) therapy in cisplatin-ineligible locally advanced/metastatic urothelial carcinoma (mUC): Primary analysis of IMvigor210 cohort 1.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Atezolizumab; Medicine; Metastatic Urothelial Carcinoma; Oncology; Cohort; Internal medicine; Cisplatin; Clinical Oncology; Urothelial carcinoma; Bladder cancer; Cancer; Chemotherapy; Immunotherapy; Nivolumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001174613,0.0003294949,0.0009209943,0.0002413435,0.0002072785,0.001127528,0.0004611922,0.0005214568,0.003141189],"category_scores_gemma":[0.001414765,0.0002863491,0.001267993,0.0004233919,0.0002001363,0.0006469496,0.0004162531,0.001054462,0.0006272054],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005246024,"about_ca_system_score_gemma":0.0005682211,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00163488,"about_ca_topic_score_gemma":0.006514903,"domain_scores_codex":[0.9995889,0.000148984,0.0000208992,0.0001138889,0.00004770934,0.00007974905],"domain_scores_gemma":[0.9992883,0.0001383461,0.0002246868,0.0001069212,0.00003608938,0.0002057925],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.136989,0.002191318,0.6615947,0.00156129,0.006238506,0.0007740237,0.0003441191,0.003391571,0.01522191,0.0006879084,0.03493088,0.1360748],"study_design_scores_gemma":[0.01598088,0.02195684,0.9336168,0.0003368087,0.004732318,0.001793813,0.0003664974,0.004351677,0.001913552,0.000721899,0.01415457,0.00007438906],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9826869,0.005801569,0.0002377051,0.0004443835,0.00008317745,0.00009679038,0.008780772,0.00004163946,0.001827057],"genre_scores_gemma":[0.9842041,0.001975669,0.000234172,0.0005248364,0.0001132091,0.00007596944,0.01127287,0.0000241875,0.001574954],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003141189,"threshold_uncertainty_score":0.01050836,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0732569150031822,"score_gpt":0.4317699527936819,"score_spread":0.3585130377904996,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}